

# Luis Calzadilla Bertot

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2022206/luis-calzadilla-bertot-publications-by-year.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24  
papers

2,194  
citations

15  
h-index

26  
g-index

26  
ext. papers

2,858  
ext. citations

5.8  
avg. IF

5.13  
L-index

#	Paper	IF	Citations
24	REPLY. <i>Hepatology</i> , <b>2021</b> , 74, 531-532	11.2	
23	Serum Fibrosis Tests Guide Prognosis in Metabolic Dysfunction-Associated Fatty Liver Disease Patients Referred From Primary Care. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	1
22	Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 136-145.e6	6.9	19
21	ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. <i>Hepatology</i> , <b>2021</b> , 73, 2238-2250	11.2	7
20	Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand. <i>Liver Transplantation</i> , <b>2019</b> , 25, 25-34	4.5	16
19	Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2019</b> , 13, 179-187	4.2	26
18	Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2018</b> , 38, 1793-1802	7.9	47
17	Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. <i>Gastroenterology</i> , <b>2018</b> , 155, 443-457.e17	13.3	308
16	Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH. <i>Liver International</i> , <b>2017</b> , 37, 1887-1896	7.9	37
15	Role of Exercise in NAFLD/NASH: What is the Right Prescription?. <i>Current Hepatology Reports</i> , <b>2017</b> , 16, 356-365	1	
14	Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma. <i>Hepatology Communications</i> , <b>2017</b> , 1, 53-60	6	39
13	Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 283-90	3.3	25
12	The Natural Course of Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	321
11	Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. <i>Hepatology</i> , <b>2016</b> , 63, 1875-87	11.2	41
10	Reply. <i>Hepatology</i> , <b>2016</b> , 64, 2266-2267	11.2	
9	Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , <b>2015</b> , 149, 367-78.e5; quiz e14-5	13.3	1010
8	Arterial blood pressure is closely related to ascites development in compensated HCV-related cirrhosis. <i>PLoS ONE</i> , <b>2014</b> , 9, e95736	3.7	4

7	Risk factors associated with the development of hyperamylasemia and post-ERCP pancreatitis in the Cuban National Institute. <i>Revista De Gastroenterologia Del Peru: Organo Oficial De La Sociedad De Gastroenterologia Del Peru</i> , <b>2014</b> , 34, 127-32	0.3	2
6	The natural history of compensated HCV-related cirrhosis: a prospective long-term study. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 434-44	13.4	59
5	Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review. <i>European Radiology</i> , <b>2011</b> , 21, 2584-96	8	112
4	Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial. <i>BMJ Open</i> , <b>2011</b> , 1, e000140	3	9
3	Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 2638-47	5.6	29
2	Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 999-1009	6.1	73
1	Application of a biochemical and clinical model to predict individual survival in patients with end-stage liver disease. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 2768-77	5.6	9